PROGRESSIVE VESTIBULAR SCHWANNOMA (VS)

Clinical trials for PROGRESSIVE VESTIBULAR SCHWANNOMA (VS) explained in plain language.

Never miss a new study

Get alerted when new PROGRESSIVE VESTIBULAR SCHWANNOMA (VS) trials appear

Sign up with your email to follow new studies for PROGRESSIVE VESTIBULAR SCHWANNOMA (VS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Drug trial aims to slow tumor growth in rare genetic disorder

Disease control Completed

This study tested whether the oral drug crizotinib could slow or reduce the growth of vestibular schwannoma tumors in people with Neurofibromatosis Type 2 (NF2). Twelve participants with NF2 and confirmed tumor progression took crizotinib daily in 28-day cycles, for up to one yea…

Matched conditions: PROGRESSIVE VESTIBULAR SCHWANNOMA (VS)

Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

PROGRESSIVE VESTIBULAR SCHWANNOMA (VS)

Get alerted when new PROGRESSIVE VESTIBULAR SCHWANNOMA (VS) trials appear

Drug trial aims to slow tumor growth in rare genetic disorder